Company intelligence / Profile preview
CellOrigin Biotech
Hangzhou, Zhejiang, Chinaen.cell-origin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CellOrigin Biotech is advancing a pipeline of allogeneic "off-the-shelf" iPSC-derived immune cell therapies targeting solid tumors. Its lead asset SY-001 is in Phase 1 clinical trials for pancreatic cancer. The company has established proprietary platforms for generating engineered macrophages and NK cells from pluripotent stem cells using advanced gene editing techniques. Early-stage results have enabled strategic partnerships with major pharma companies to accelerate development toward commercialization.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyInduced pluripotent stem cell derived therapyCAR-T cell therapy (specifically CAR-macrophage, CAR-NK)mRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Qilu Pharmaceutical — global collaboration on development/manufacturing/commercialization of off-the-shelf iPSC-derived CAR-macrophages for oncology indicationsCATUG — partnership focused on manufacturing/development of mRNA-LNP delivered CAR-based immunotherapies
Beyond the preview
Go deeper on CellOrigin Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellOrigin Biotech.